What Marinova does

Marinova Pty Ltd is an Australian biotechnology company founded in 2003 and headquartered in Cambridge, Tasmania. The company researches, develops, and manufactures high purity fucoidan compounds, a class of sulfated polysaccharides extracted from brown seaweeds (primarily Undaria pinnatifida and Fucus vesiculosus). Its core technological asset is the Maritech proprietary aqueous extraction process, a six-stage water-based procedure (seaweed selection, aqueous extraction, proprietary filtration, concentration, dehydration, quality testing) that produces fucoidan extracts without organic solvents, preserving chemical structure and bioactivity. Marinova operates from a single API-standard, ISO 9001 / HACCP / GMP-certified manufacturing site housing both production and research laboratories, sourcing wild seaweed from Tasmania, Patagonia, Nova Scotia, and Brittany.

The company sells exclusively through a B2B model, with no consumer-facing products. Its customer base spans six verticals: nutraceutical and dietary supplement manufacturers (primary), skincare and dermatology brands, pharmaceutical and medical device companies, veterinary and animal health firms, nutricosmetics, and functional food and beverage producers. Revenue is generated through one-time sales of branded extracts (Maritech for nutritional/cosmetic/animal applications, Fucorich for functional foods/beverages, MariVet for veterinary use), custom-characterized fucoidan fractions for medical device and pharmaceutical development, and research-grade reference samples. Pricing is quote-based given the custom and scientific nature of the products; specific pricing is not publicly disclosed. Sales are conducted via direct engagement with brand owners, formulators, and research institutions globally, supported by an extensive evidence base of more than 4,000 peer-reviewed publications on fucoidan bioactivity and stacked regulatory clearances (FDA GRAS, EU Novel Foods, USDA NOP, EU Organic, COSMOS, Kosher, Halal).

Marinova has no disclosed institutional investors, no parent company, and no public listing, appearing to be founder/management-owned since inception. The company has recently tripled production capacity (2026), added 33% more functional food and beverage customers year-over-year, and expanded research collaborations into oncology, neuroprotection, gut health, exercise performance, and prebiotic positioning.

Name

Marinova

Legal name

Marinova Pty Ltd

Website

https://marinova.com.au

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Marinova Pty Ltd is an Australian biotechnology company that researches, develops, and manufactures high purity fucoidan extracts from brown seaweeds using proprietary solvent-free aqueous extraction technology. It serves B2B customers across nutraceutical, pharmaceutical, skincare, veterinary, and functional food sectors globally.

Ownership category

akta.pro rank

Product category

Marine biotechnology ingredients

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Agar, Carrageenan & Alginates (Seaweed Hydrocolloids) (AFAJABAE)

Keywords

• High purity fucoidan
• Marine biotechnology extracts
• Brown seaweed ingredients
• Nutraceutical active ingredients
• Pharmaceutical fucoidan fractions

Headquarters

HQ city

Hobart

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Maritech® Organic Fucoidan Extracts: Sale of high purity, certified organic fucoidan extracts (Undaria pinnatifida and Fucus vesiculosus) for nutritional, cosmetic, and animal health applications under the Maritech® brand.
2. Pharmaceutical & Medical Device Fucoidans: Sale of highly characterised fucoidan fractions for medical device applications and pharmaceutical research, including depyrogenated fractions with defined biological activities.
3. Research Samples & Reference Standards: Supply of species-specific fucoidan extracts for research, analysis, and quality verification by formulators and contract manufacturers.
4. Fucorich® Functional Food Ingredient: Certified organic natural ingredient featuring fucoidan combined with marine mannitol for functional food and beverage applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Marinova researches, develops and manufactures high purity, certified organic fucoidan compounds extracted from brown seaweeds (Undaria pinnatifida and Fucus vesiculosus) using a proprietary aqueous extraction process that avoids harsh solvents. The company sells branded Maritech organic fucoidan extracts as B2B active ingredients for nutraceutical, skincare, veterinary, and functional food applications, alongside customised characterised fucoidan fractions for pharmaceutical research and medical device development, and species-specific research reference samples.

Product overview

Marinova is an Australian biotechnology company specializing in the research, development, and manufacture of high purity fucoidan compounds extracted from brown seaweeds. The company operates as a unified portfolio centered on its proprietary aqueous extraction technology, producing products across two main tiers: Maritech® Organic Fucoidan as the branded consumer/industry-facing product line for nutritional, cosmetic, and animal health applications; and Custom Fucoidan Extracts for advanced pharmaceutical and medical device research. Supporting products include Fucorich® for functional foods and beverages, MariVet® for veterinary applications, and Research Fucoidan Samples for scientific analysis. The company positions itself as the world's only producer of high purity, certified organic fucoidan with global regulatory acceptance.

Differentiator

Problem solved

Functional benefit

Products and services

• Maritech Organic Fucoidan

Quantifiable outcome

• In clinical study, high purity fucoidan increased cytotoxic T cells and Natural Killer cell levels after 3 days, with continual increase in phagocytic activity of monocytes and granulocytes over 28-day period
• +4 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Griffith University - Mucosal Immunology Research GroupcoreStrategic or Co-development Partner · 1 January 2019Research collaboration led by Dr Amanda Cox investigating effects of fucoidan on gut health and immune function in high performance athletes. Study published in Marine Drugs journal.
• Brisbane Lions Australian Rules Football ClubminorStrategic or Co-development Partner · 1 January 2019Professional athletes from the club participated in research study investigating gut health and immune function benefits of fucoidan supplementation. Part of collaboration between Griffith University and Marinova.
• ProDigestcoreStrategic or Co-development PartnerProDigest provides exclusive access to the SHIME® (Simulator of the Human Intestinal Microbial Ecosystem) validated in vitro gut model. Collaboration on research exploring effects of Marinova's fucoidan on colonic microbiome. Dr Massimo Marzorati, CEO of ProDigest, co-authored published research paper on gut health benefits.
• University Research Institutions (Various)coreStrategic or Co-development PartnerMarinova collaborates with leading universities and contract research organisations globally for human clinical trials and advanced research. Maintains established global research network. Company scientists co-author peer-reviewed publications and contribute to pharmaceutical development research.
• University of South AustraliacoreStrategic or Co-development PartnerOngoing research project examining polyelectrolyte multilayers (PEMs) for wound healing and drug delivery applications using Marinova's fucoidan. Multiple papers published including research on FGF-2 incorporation into fucoidan/chitosan PEMs.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Cargill, Inc. (Algal Ingredients): Global agribusiness with a growing portfolio of algae-derived functional ingredients for food, beverage, and animal nutrition. It is comparable to Marinova as a B2B supplier of naturally-derived, science-backed functional ingredients to consumer goods manufacturers.
• CP Kelco: Global specialty hydrocolloid and fermentation ingredient producer (pectin, carrageenan, gellan gum, xanthan). It is comparable to Marinova as a B2B supplier of high-purity functional polysaccharides to food, beverage, and personal care formulators, though at much broader scale and without fucoidan specialization.
• Ingredion Incorporated: Global ingredient solutions provider specializing in plant-based sweeteners, starches, and functional ingredients for food, beverage, and personal care. It is comparable to Marinova as a specialty B2B ingredient supplier with strong regulatory documentation and formulation support.
• DSM-Firmenich: Global nutrition, health, and specialty ingredients major with a broad portfolio including prebiotics, vitamins, and marine-sourced bioactives. It is comparable to Marinova as a supplier of science-backed, regulatory-grade functional ingredients to nutraceutical, food, and personal care customers.
• Kerry Group plc: Global taste and nutrition group supplying functional ingredients, bioactive systems, and clean-label solutions to food, beverage, and pharma customers. It is comparable to Marinova as a B2B platform supplier of science-validated functional ingredients into mainstream CPG and supplement formulations.
• Roquette Frères: Global leader in plant-based ingredients (starches, polyols, proteins, fibers) serving food, nutrition, and pharma markets. It is comparable to Marinova in providing high-purity, regulated, naturally-derived excipients and functional ingredients to B2B customers in nutrition and pharmaceuticals.
• Corbion N.V. Dutch specialty ingredients company with leading positions in algae-based ingredients (including algae-derived omega-3s and functional proteins) and food preservation. It is comparable to Marinova in selling high-purity, science-backed, naturally-sourced bioactive ingredients to B2B customers in food, nutrition, and personal care.

Direct peers

• Gelymar S.A. Chilean producer of seaweed-derived hydrocolloids (carrageenan, agar, alginates) from wild-harvested algae. It is comparable to Marinova in extracting and refining high-purity seaweed polysaccharides for global B2B food, supplement, and personal care customers.
• Kanehide Bio Co., Ltd. Okinawa-based Japanese producer of fucoidan and other brown seaweed extracts for nutraceutical and functional food applications. It is the closest direct global peer to Marinova in the high-purity fucoidan category, competing in the same ingredient category and end markets.
• Fuji Oil Holdings: Japanese specialty ingredient group producing plant-based and algae-derived proteins and polysaccharides, including fucoidan. It is comparable to Marinova in combining proprietary extraction technology with regulatory-grade functional ingredients for global B2B customers in food and nutrition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/marinova-pty-ltd

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marinova